TearLab (TearLab) Short-Term Debt : $38.02 Mil (As of Mar. 2020)

View and export this data going back to 2004. Start your Free Trial

What is TearLab Short-Term Debt?

TearLab's Short-Term Debt for the quarter that ended in Mar. 2020 was $38.02 Mil.

TearLab's quarterly Short-Term Debt increased from Sep. 2019 ($25.55 Mil) to Dec. 2019 ($36.58 Mil) and increased from Dec. 2019 ($36.58 Mil) to Mar. 2020 ($38.02 Mil).

TearLab's annual Short-Term Debt stayed the same from Dec. 2017 ($0.00 Mil) to Dec. 2018 ($0.00 Mil) but then increased from Dec. 2018 ($0.00 Mil) to Dec. 2019 ($36.58 Mil).

TearLab Short-Term Debt Historical Data

The historical data trend for TearLab's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TearLab Short-Term Debt Chart

TearLab Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Short-Term Debt

Get a 7-Day Free Trial

36.58

TearLab Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20
Short-Term Debt	Get a 7-Day Free Trial															7.98	16.49	25.55	36.58	38.02

TearLab Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

TearLab Short-Term Debt Related Terms

Thank you for viewing the detailed overview of TearLab's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

TearLab (TearLab) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » TearLab Corp (OTCPK:TEAR) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

150 LaTerraza Boulevard, SuiteÂ 101, Escondido, CA, USA, 92025

Website

http://www.tearlab.com

TearLab Corp is a part of the diagnostic industry. It is an in-vitro diagnostic company based in the United States. TearLab has commercialized a proprietary tear testing platform, the TearLab Osmolarity System that enables eye care practitioners to test for highly sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The company operates through its wholly-owned subsidiary, TearLab Research Inc. Most of the company's revenue is derived from the United States region.

Executives

Anthony E Altig	director	C/O OPTIMER PHARMACEUTICALS, INC, 101 HUDSON STREET, JERSEY CITY NJ 07302
Cr Group L.p.	10 percent owner	1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Lindstrom Richard L Md	director	2811 WESTWOOD PL, WAYZATA MN 55391
Awm Investment Company, Inc.	10 percent owner	527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022
Adrienne L Graves	director	125 STONE MOUNTAIN CIRCLE, NAPA CA 94558
Gilbert S Omenn	director	AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
John Y Caloz	officer: Chief Financial Officer	ETON AVE, C/O INTERNATIONAL REMOTE IMAGING SYS, CHATSWORTH CA 91311